Literature DB >> 26146916

One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.

Marta A Miyares1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26146916     DOI: 10.1001/jamainternmed.2015.1271

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  2 in total

1.  Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.

Authors:  Inmaculada Hernandez; Yuting Zhang
Journal:  Am J Cardiovasc Drugs       Date:  2017-02       Impact factor: 3.571

2.  Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.

Authors:  Inmaculada Hernandez; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-07       Impact factor: 21.873

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.